Thursday, March 13, 2025
spot_img

Notice of Knight Therapeutics’ Fourth Quarter and Year End 2024 Results Conference Call

MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 financial results on Thursday, March 20, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date: Thursday, March 20, 2025
Time: 8:30 a.m. ET
Telephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677  
Webcast: www.knighttx.com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.
Replay: An archived replay will be available for 30 days at www.knighttx.com.

________________________________________

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2023, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact:    
Knight Therapeutics Inc.

   
Samira Sakhia   Arvind Utchanah
President & Chief Executive Officer   Chief Financial Officer
T: 514.484.4483   T. +598.2626.2344
F: 514.481.4116    
Email: [email protected]   Email: [email protected]
Website: www.knighttx.com   Website: www.knighttx.com

Powered by SlickText.com

Hot this week

Middlefield Canadian Income PCC: Net Asset Value(s)

Middlefield Canadian Income PCC Net Asset Value ...

Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology...

Trading in Rovsing A/S shares by board members, executives and associated persons

          13 March 2025 Announcement no. 378 Trading...

Rogers Recognized as Canada’s Most Reliable Internet by Opensignal

Canada’s largest cable network delivers most consistent experience for...

Aclarion Provides Shareholder Update

BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE)...

Topics

Middlefield Canadian Income PCC: Net Asset Value(s)

Middlefield Canadian Income PCC Net Asset Value ...

Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology...

Trading in Rovsing A/S shares by board members, executives and associated persons

          13 March 2025 Announcement no. 378 Trading...

Rogers Recognized as Canada’s Most Reliable Internet by Opensignal

Canada’s largest cable network delivers most consistent experience for...

Aclarion Provides Shareholder Update

BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE)...

Acme United Corporation Board Approves Cash Dividend

SHELTON, Conn., March 13, 2025 (GLOBE NEWSWIRE)...

ALPHAMIN TEMPORARILY CEASES MINING OPERATIONS

GRAND BAIE, MAURITIUS, March 13, 2025 (GLOBE...
spot_img

Related Articles

Popular Categories

spot_img